The Eighth Circuit Court of Appeals recently upheld the dismissal of a lawsuit filed by United HealthCare Services, Inc. against AmerisourceBergen Corporation and its subsidiaries. The court ruled that United HealthCare's claims were barred by the statute of limitations, meaning they were filed too late. This decision affects United HealthCare and potentially other parties involved in similar claims against pharmaceutical companies.
The case, United HealthCare Services, Inc. v. AmerisourceBergen Corporation, was filed on July 31, 2026, under docket number 25-3205. The central issue revolved around allegations that AmerisourceBergen engaged in fraudulent activities related to the distribution of adulterated oncology drugs. United HealthCare claimed that these drugs were administered to patients across the country, including those insured under its programs.
The dispute began when United HealthCare accused AmerisourceBergen and its subsidiaries of running an unlawful scheme known as the Pre-Filled Syringe Scheme. This scheme allegedly involved repackaging drugs in a manner that violated federal regulations. United HealthCare argued that it reimbursed claims for these adulterated drugs, which were dangerous and not fit for patient use. The case reached the Eighth Circuit after a district court dismissed the complaint on multiple grounds, including the assertion that it was untimely.
In its ruling, the Eighth Circuit affirmed the lower court's decision to dismiss United HealthCare's claims. The judges noted that the statute of limitations for the claims was six years, and the court found that United HealthCare should have been aware of the fraudulent activities well before it filed its lawsuit in 2023. The court stated, "UHS did not file its suit until 2023, after the six-year statute of limitations expired." This ruling was based on the court's conclusion that United HealthCare had enough information about the alleged fraud by 2016, which triggered the statute of limitations.
The court further explained that United HealthCare's claims of fraudulent concealment did not sufficiently demonstrate that it could not have discovered the alleged fraud earlier. The judges pointed out that United HealthCare had access to various public disclosures, including Securities and Exchange Commission (SEC) filings and news reports, which indicated ongoing investigations into AmerisourceBergen's practices.
The impact of this ruling is significant. It reinforces the importance of timely filing lawsuits, especially in cases involving fraud. The decision may deter other potential plaintiffs from pursuing similar claims if they cannot demonstrate that they acted within the statute of limitations. Additionally, it highlights the necessity for companies to maintain transparency, as public disclosures can affect legal proceedings.
Looking ahead, it is unclear whether United HealthCare will seek to appeal the decision further. The court's ruling leaves little room for argument regarding the statute of limitations. However, there may be related cases or claims against AmerisourceBergen or other pharmaceutical companies that could arise in the future, especially as more information about drug safety and distribution practices comes to light.